Last reviewed · How we verify

NCT05878951

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

Recruiting now Phase 2, PHASE3 Last updated 20 January 2026
What this trial tests

Phase 2, PHASE3 trial testing OnabotulinumtoxinA in Urinary Incontinence in 80 participants. Currently enrolling.

Timeline
13 July 2023
Primary endpoint
1 May 2026
24 August 2026

Quick facts

Lead sponsorNorthwestern University
PhasePhase 2, PHASE3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment80
Start date13 July 2023
Primary completion1 May 2026
Estimated completion24 August 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Northwestern University

Who can join

Adults 18 to 89, male only, with Urinary Incontinence or Overactive Bladder Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of OnabotulinumtoxinA

Trials testing the same drug.

Other recruiting trials for Urinary Incontinence

Currently open trials in the same condition.

Other Northwestern University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05878951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing